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882Objectives:We sought to identify risk factors for mortality and morbidity during the Norwood hospitalization in
newborn infants with hypoplastic left heart syndrome and other single right ventricle anomalies enrolled in the
Single Ventricle Reconstruction trial.
Methods: Potential predictors for outcome included patient- and procedure-related variables and center volume and
surgeon volume. Outcome variables occurring during theNorwood procedure and before hospital discharge or stage
II procedure includedmortality, end-organcomplications, lengthofventilation, andhospital lengthof stay.Univariate
and multivariable Cox regression analyses were performed with bootstrapping to estimate reliability for mortality.
Results: Analysis included 549 subjects prospectively enrolled from 15 centers; 30-day and hospital mortality
were 11.5% (63/549) and 16.0% (88/549), respectively. Independent risk factors for both 30-day and hospital
mortality included lower birth weight, genetic abnormality, extracorporeal membrane oxygenation (ECMO) and
open sternum on the day of the Norwood procedure. In addition, longer duration of deep hypothermic circulatory
arrest was a risk factor for 30-day mortality. Shunt type at the end of the Norwood procedurewas not a significant
risk factor for 30-day or hospital mortality. Independent risk factors for postoperative renal failure (n¼ 46), sep-
sis (n ¼ 93), increased length of ventilation, and hospital length of stay among survivors included genetic ab-
normality, lower center/surgeon volume, open sternum, and post-Norwood operations.
Conclusions: Innate patient factors, ECMO, open sternum, and lower center/surgeon volume are important risk
factors for postoperative mortality and/or morbidity during the Norwood hospitalization. (J Thorac Cardiovasc
Surg 2012;144:882-95)Risk factors for hospital morbidity and mortality after the
Norwood procedure for patients with hypoplastic left heart
syndrome (HLHS) have been reported from single centers
and multicenter databases. Many centers report low birth
weight, genetic abnormalities, restrictive atrial septum, du-
ration of cardiopulmonary bypass (CPB), and extracorpo-
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Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
CPR ¼ cardiopulmonary resuscitation
DHCA ¼ deep hypothermic circulatory arrest
ECMO ¼ extracorporeal membrane oxygenation
E-CPR ¼ ECMO required to restore circulation
during CPR
HLHS ¼ hypoplastic left heart syndrome
MBTS ¼ modified Blalock-Taussig shunt
RCP ¼ regional cerebral perfusion
RVPAS ¼ right ventricular–pulmonary artery shunt
SVR ¼ Single Ventricle Reconstruction
Tabbutt et al Congenital Heart Disease
C
H
DPrimary results of the SVR trial reported differences in out-
come between subjects undergoing the Norwood procedure
with a right ventricular–pulmonary artery shunt (RVPAS)
versus a modifiedBlalock-Taussig shunt (MBTS).17 The ini-
tial report focused solely on the comparative outcomes rela-
tive to shunt type. The primary aim of this prespecified
secondary analysis was to examine the associations of
patient-related risk factors and perioperative management
variables on morbidity and mortality during the Norwood
hospitalization. To facilitate comparisons with previous re-
ports of surgical morality for theNorwood procedure, we an-
alyzed both 30-day and hospital mortality. Our secondary
aim was to explore associations with shunt type on longer-
term transplant-free survival in subjects requiring cardiopul-
monary resuscitation (CPR) and/or ECMO.METHODS
Study Design
Details of the SVR trial design have been previously published.17,18 In
brief, inclusion criteria consisted of a diagnosis of HLHS or other single
right ventricle anomaly and a planned Norwood procedure. Patients were
excluded if the preoperative cardiac anatomy rendered either the MBTS
or RVPAS technically impossible or if they had any major congenital or
acquired extracardiac abnormality that could independently decrease the
likelihood of transplant-free survival at 1 year of age. Subjects were ran-
domly assigned to receive either theMBTS or the RVPAS. The institutional
review board at each center approved the protocol. Written informed con-
sent was obtained from a parent/guardian before randomization. Other than
the type of shunt placed, the remainder of the perioperative care was per
institutional standard. For the purposes of this analysis, subjects were cat-
egorized by the shunt in place at the end of the Norwood procedure.
Data Collection and Definitions
Datawere prospectively collected. The 16 outcomevariables are defined
in Appendix Table 1. Other than 30-day mortality, outcomes were recorded
if they occurred before hospital discharge or before stage II procedure for
subjects not discharged. ECMO initiated after the Norwood procedure
was considered an outcome variable. The 42 potential risk factors are de-
fined in Appendix Table 2. Subjects underwent genetic evaluations when
indicated by clinical suspicion of a genetic abnormality. In addition, a re-
search option for a genetic evaluation was offered. Preoperative shockThe Journal of Thoracic and Cawas defined as a composite of hepatic failure (Appendix Table 1), renal fail-
ure (Appendix Table 1), lactate greater than 10 mmol/L, or intubation for
shock. Perfusion strategies included deep hypothermic circulatory arrest
(DHCA) alone or regional cerebral perfusion (RCP) with or without
DHCA. Open sternum included all subjects with an open sternum on the
day of the Norwood procedure. These subjects were categorized as those
at a ‘‘routine’’ center where sternums of all patients were left open at the
end of the Norwood procedure or those at an ‘‘elective’’ center where the
surgeon selectively decided to leave the patient’s sternum open. ECMO
for failure to separate from CPB was examined as a potential risk factor.
The day of Norwood procedure was defined as day 1.
The longer-term outcome of patients requiring CPR (defined as receiv-
ing chest compressions) and/or ECMO was examined in further detail.
Subjects were characterized as follows: CPR alone (CPR), ECMO alone
(ECMO), ECMO required to restore circulation during CPR (E-CPR),
and neither CPR nor ECMO (‘‘none’’). For the subanalysis of these 4
groups, only CPR, ECMO, or E-CPR occurring within 30 days of Norwood
procedure were included. Subjects requiring ECMO for failure to separate
from CPB were included in the ECMO group.
Statistical Methods
Summary statistics include mean  standard deviation, median, and
range. We analyzed 2 mortality outcomes: (1) time to death up to discharge
from the Norwood hospitalization, using Kaplan-Meier estimation and Cox
proportional hazards regression, with censoring at dates of cardiac trans-
plant and at time of stage II procedure (for those not discharged) and (2) a di-
chotomous 30-day post-Norwood procedure mortality indicator, using
logistic regression. We analyzed 4 continuous outcomes using linear
regression: post-Norwood right ventricular fractional area change, log-
transformed time to initial extubation, log-transformed total days venti-
lated, and log-transformed hospital length of stay. Subjects who died or
underwent cardiac transplant during the hospitalization were excluded
from analysis of the extubation, ventilation, and length of stay outcomes.
We analyzed 10 dichotomousmorbidity outcomes using logistic regression;
for 3 of these (necrotizing enterocolitis, liver failure, mediastinitis), only
univariate analyses were conducted owing to the low event rate. For con-
struction ofmultivariablemodels, variableswith aP value .2 in univariate
analysis were used as candidate predictors in regression modeling. The R2
and maximum rescaled R2 values are reported for linear and logistic regres-
sion models, respectively. In addition, generalized additive modeling was
used to identify nonlinear associations between outcomes and continuous
candidate predictors. Variables with a nonlinearity P value<.05 were con-
sidered in the multivariable selection procedure. Bootstrap resampling was
used to estimate the reliability of each factor selected by stepwise regression
for the multivariable mortality model.19,20 We retained a term in the model
if it had reliability greater than 50% and a P value of less than .05.
Weusedanalysis of variance and theKruskal-Wallis test for comparisonof
the distributions of baseline characteristics across the 4 ECMO/CPR groups.
To account for potential survival bias in this secondary analysis of CPR with
orwithoutECMOsubjects,weusedCoxproportional hazards regressionwith
a time-dependent group indicator to model time to death or transplant, using
all available follow-up data. A test of interaction between subject group and
shunt type was used to assess differential treatment effect by group.RESULTS
Between May 2005 and July 2008 there were 549 evalu-
able SVR subjects: 268 with an MBTS and 281 with an
RVPAS.Mortality
Mortality during the Norwood hospitalization was 16%
(88/549). Deaths occurred at a median of 16 days, (range,rdiovascular Surgery c Volume 144, Number 4 883
FIGURE 1. Kaplan-Meier estimates and pointwise 95% confidence
bands for hospital survival after the Norwood procedure (N ¼ 549). Pa-
tients were censored when they were transplanted (n ¼ 9) or discharged
(n ¼ 430).
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D1-149 days). The 30-day mortality was 12% (63/549).
Figure 1 shows the Kaplan-Meier survival curve for all sub-
jects during the Norwood hospitalization. Included among
the survivors were 9 subjects who underwent cardiac trans-
plantation before discharge; median time to transplant was
51 days after the Norwood procedure (range, 9-270 days).
There were 22 subjects who remained in the hospital until
the stage II procedure; median time to stage II procedure
was 116 days (range, 49-271 days).
Significant risk factors by univariate analysis for 30-day
mortality included the following: lower birth weight, lower
gestational age, genetic abnormality, duration of DHCA,
duration of total support time, ECMO for failure to separate
from CPB, open sternum at the Norwood procedure, and
surgeon Norwood volume. Additional risk factors by uni-
variate analysis for Norwood hospital mortality included
preoperative intervention on the atrial septum and youngerTABLE 1. Independent risk factors for 30-day and hospital mortality afte
Candidate predictor
Thirty-day mortality
Odds ratio 95% CI P
Birth weight, kg 0.52 (0.29, 0.94) .0
Genetic abnormality <.0
Yes 2.93 (0.78, 10.9)
No Ref
Unknown 13.6 (6.23, 29.5)
DHCA duration, min 1.10 (1.03, 1.19) .0
ECMO at Norwood procedure 4.38 (1.76, 10.9) .0
Open sternum <.0
Yes, routine site 18.1 (5.17, 63.4)
Yes, elective site 5.81 (1.75, 19.3)
No, elective site Ref
CI, Confidence interval; DHCA, deep hypothermic circulatory arrest; ECMO, extracorpor
884 The Journal of Thoracic and Cardiovascular Surgage at surgery. Significant risk factors bymultivariable anal-
ysis, for 30-day and hospital mortality, are shown in Table 1.
Shunt type was not a significant risk factor for mortality.
ECMO and open sternum on the day of the Norwood proce-
dure were the strongest risk factors for mortality. ECMO
was initiated during the Norwood procedure in 8% of sub-
jects with open sternum and 1% of subjects with closed
sternum (P ¼ .002). Open sternum remained a significant
risk factor for mortality with ECMO included in the multi-
variable model. Sternums were routinely left open in all pa-
tients at 7 centers (median hospital mortality, 18%; range,
2%-39%) and sternums were electively left open at 8 cen-
ters (median hospital mortality, 13%; range, 0%-30%).
The 7 routine open sternum centers represented 59%
(244/415) of the subjects with open sternum. The mortality
risk of open sternum did not differ significantly between
routine and elective centers. For the open sternum cohort,
reliability by bootstrapping methodology for hospital mor-
tality was high at 90%. Although subjects with the ana-
tomic subtype of mitral stenosis with aortic atresia were
more likely to require ECMO during the Norwood proce-
dure (13% vs 4%; P< .001), mitral stenosis with aortic
atresia was not an independent risk factor for 30-day
(P ¼ .23) or hospital (hazard ratio, 1.48; 95% confidence
interval, 0.92-2.36; P ¼ .1) mortality.Morbidity
Results of multivariable analyses for the morbidity out-
comes are shown in Table 2. Shunt type was only an inde-
pendent risk factor for CPR (odds ratio, 2.02; P ¼ .005)
and decreased ventricular function as measured by postop-
erative echocardiographic fractional area change (odds ra-
tio,3.59; P< .001) with the MBTS compared with the
RVPAS. Genetic abnormality, center volume, surgeon vol-
ume, open sternum, and post-Norwood operations were
the most common independent risk factors for post-
Norwood morbidities.r the Norwood procedure
Hospital mortality
Hazard ratio 95% CI P Reliability
3 0.62 (0.41, 0.93) .02 63%
01 <.001 81%
2.89 (1.21, 6.9)
Ref
6.42 (3.67, 11.2)
1
02 3.41 (1.94, 5.98) <.001 69%
01 .002 90%
5.87 (2.22,15.6)
4.25 (1.65, 10.6)
Ref
eal membrane oxygenation; Ref, reference group.
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TABLE 2. Multivariable models for morbidity outcomes after the Norwood procedure
Outcome
No. of subjects
with event
Time to event, days;
median (range)
Odds
ratio 95% CI P
Catheter intervention (R2 ¼ 7%) 27 27 (2-129)
Preoperative intubation for apnea/transport 0.23 (0.05, 0.97) .05
Left atrial decompression 4.02 (1.19, 13.6) .03
Regional cerebral perfusion 2.11 (1.04, 4.29) .04
Central nervous system injury (R2 ¼ 4%) 38 5 (1-157)
Genetic abnormality .01
Yes 2.84 (1.29, 6.28)
No Ref
Unknown 2.68 (1.27, 5.64)
Renal failure (R2 ¼ 26%) 46 3 (1-77)
Anomalous pulmonary venous return 10.2 (2.43, 42.4) .002
Preoperative intubation for apnea/transport 3.46 (1.66, 7.21) <.001
Heart block 18.8 (5.05, 70) <.001
Open sternum .02
Yes, routine site 7.61 (1.86, 31.2)
Yes, elective site 6.72 (1.62, 27.9)
No, elective site Ref
Surgeon Norwood volume .006
5/y 0.31 (0.09, 1.09)
6 to 10/y 0.90 (0.28, 2.91)
11 to 15/y 0.20 (0.06, 0.61)
>15/y Ref
Center volume .02
15/y 1.55 (0.53, 4.58)
16 to 20/y 0.44 (0.14, 1.45)
21 to 15/y 0.32 (0.11, 0.91)
>30/y Ref
Sepsis (R2 ¼ 16%) 93 19 (1-133)
Gestational age, wk 0.79 (0.68, 0.92) .002
AS/MS/VSD 3.81 (1.05, 13.9) .04
Duration of DHCA, min 1.07 (1.004, 1.13) .04
Open sternum duration, d 1.08 (1.05, 1.12) <.001
Center volume .003
15/y 2.28 (1.17, 4.47)
16 to 20/y 0.94 (0.40, 2.19)
21 to 30/y 0.64 (0.33, 1.26)
>30/y Ref
ECMO after Norwood procedure (R2 ¼ 40%) 56 2 (1-149)
Birth weight<2.5 kg .04
Yes 2.38 (1.04, 5.44)
No Ref
Age at Norwood procedure, d 0.87 (0.78, 0.98) .02
Operations after Norwood procedure 2.23 (1.84, 2.69) <.01
CPR (R2 ¼ 25%) 97 5 (1-149)
Birth weight, kg 0.54 (0.34, 0.85) .008
Genetic abnormality <.001
Yes 0.32 (0.17, 0.62)
No 0.28 (0.16, 0.49)
Unknown Ref
Shunt .005
MBTS 2.02 (1.23, 3.32)
RVPAS Ref
Operations after Norwood procedure 1.51 (1.32, 1.73) <.001
(Continued)
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TABLE 2. Continued
Outcome
No. of subjects
with event
Time to event, days;
median (range)
Odds
ratio 95% CI P
TR (2.5 mm) (R2 ¼ 11%) 112 NA
TR (2.5 mm) preoperative 2.92 (1.55, 5.49) .001
Open sternum .003
Yes, routine site 2.11 (1.12, 3.96)
Yes, elective site 3.21 (1.66, 6.23)
No, elective site Ref
Heart block 5.29 (1.41, 19.85) .01
Outcome N Median (range) Slope or mean diff Adjusted mean P
Fractional area change,% (R2 ¼ 13%) 452 36 (12-63)
Fractional area change preoperatively,% 0.23 <.001
Shunt <.001
MBTS 3.59 32.2
RVPAS 35.8
ECMO at Norwood procedure .007
Yes 5.34 31.4
No 36.7
Log time to first extubation, d (R2 ¼ 59%) 447 5.1 (0.6-109)
Gestational age, wk 0.06 <.001
Left atrial decompression .01
Yes 0.46 5.50
No Ref 5.04
TR (2.5 mm) preoperatively .03
Yes 0.15 5.34
No Ref 5.20
Duration of regional cerebral perfusion, min 0.0002 .04
ECMO at Norwood procedure .001
Yes 0.50 5.52
No Ref 5.02
Open sternum <.001
Yes, routine site 0.55 5.49
Yes, elective site 0.45 5.38
No, elective site Ref 4.93
Duration of open sternum, d 0.02 .03
Operations after Norwood procedure 0.15 <.001
Center volume <.001
15/y 0.06 5.09
16 to 20/y 0.31 5.46
21 to 30/y 0.21 5.36
>30/y Ref 5.15
Surgeon Norwood volume <.001
5/y 0.54 5.44
6 to 10/y 0.54 5.44
11 to 15/y 0.40 5.30
>16/y Ref 4.90
Log, length of ventilation, d (R2 ¼ 59%) 447 7 (1-270)
Gestational age, wk 0.06 <.001
Genetic abnormality <.001
Yes 0.44 2.82
No Ref 2.55
Unknown 0.16 2.38
Preoperative intubation for any reason .001
Yes 0.19 2.68
No Ref 2.49
(Continued)
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TABLE 2. Continued
Outcome N Median (range) Slope or mean diff Adjusted mean P
Left atrial decompression .02
Yes 0.49 2.83
No Ref 2.34
Preoperative shock .02
Yes 0.27 2.72
No Ref 2.45
TR (2.5 mm) preoperatively .004
Yes 0.24 2.70
No Ref 2.47
Age at Norwood procedure, d 0.02 .02
Open sternum .006
Yes, routine site 0.25 2.69
Yes, elective site 0.20 2.63
No, elective site Ref 2.43
Operations after Norwood procedure 0.34 <.001
Center volume .005
15/y 0.004 2.49
16 to 20/y 0.26 2.75
21 to 30/y 0.12 2.61
>30/y Ref 2.49
Surgeon Norwood volume .008
5/y 0.33 2.71
6 to 10/y 0.27 2.65
11 to 15/y 0.21 2.59
>16/y Ref 2.38
Log, hospital length of stay, d (R2 ¼ 49%) 452 24 (6-270)
Birth weight, kg 0.01 .03
Genetic abnormality .007
Yes 0.33 3.78
No Ref 3.44
Unknown 0.06 3.5
Preoperative intubation for shock .009
Yes 0.15 3.66
No Ref 3.5
TR (2.5 mm) preoperative .04
Yes 0.15 3.65
No Ref 3.5
Duration of DHCA, min .003
45 min 0.017 3.49
>45 min Ref 3.66
Operations after Norwood procedure 0.27 <.001
Center volume <.001
15/y 0.16 3.62
16 to 20/y 0.34 3.8
21 to 30/y 0.03 3.43
>30/y Ref 3.46
CI, Confidence interval; Ref, reference group; AS/MS/VSD, aortic stenosis, mitral stenosis, ventricular septal defect; DHCA, deep hypothermic circulatory arrest; ECMO,
extracorporeal membrane oxygenation; CPR, cardiopulmonary resuscitation; MBTS, modified Blalock-Taussig; RVPAS, right ventricle–pulmonary artery shunt; TR, tricuspid
regurgitation; NA, not available; Diff, difference.
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DLess frequent morbidities were explored by univariate
analyses. Hepatic failure occurred in 16 subjects at a median
of 22 days (range, 2-159 days) after the Norwood proce-
dure. Fifty percent (8/16) of the subjects with hepatic failure
died before discharge. Significant risk factors for hepatic
failure included lower birth weight (P ¼ .02), aortic atresiaThe Journal of Thoracic and Ca(P ¼ .03), MBTS (P ¼ .04), longer support time (P ¼ .05),
and heart block on the day of the Norwood procedure
(P¼ .02). Mediastinitis occurred in 15 subjects at a median
of 8 days (range, 3-35 days) after the Norwood procedure.
Significant risk factors for mediastinitis included preopera-
tive intubation for apnea or transport (P ¼ .04), RVPASrdiovascular Surgery c Volume 144, Number 4 887
TABLE 3. Baseline characteristics of subjects requiring ECMO, CPR, E-CPR, or neither interventions (none) within the first 30 days after
Norwood procedure
Variable CPR (37) ECMO (49) E-CPR (36) None (427) P
Birth weight, kg 2.89  .7 3.12  .6 2.95  .6 3.13  .5 .09
Birth weight<2.5 kg 10 (27%) 9 (18%) 11 (31%) 46 (11%) <.001
Gestational age, wk 37.6  2.1 38.2  1.7 37.9  1.5 38.2  1.6 .20
Age at Norwood procedure, d 6.2  3.6 5.0  3.0 4.8  2.8 5.9  4.3 .11
Ascending aorta, mm* 3.1  1.4 2.8  1.5 2.9  1.8 3.2  1.8 .27
TR 2.5 mm, preoperativey 3 (9%) 3 (6%) 4 (13%) 25 (6%) .47
Fractional area change,
preoperative,%z
49  11 46  8 47  8 46  9 .34
Incidence of event within shunt type
MBTS (268) 23 (9%) 27 (10%) 22 (8%) 196 (73%)
RVPAS (281) 14 (5%) 22 (8%) 14 (5%) 231 (82%)
P .13 .37 .17
ECMO, Extracorporeal membrane oxygenation; CPR, cardiopulmonary resuscitation; E-CPR, ECMO required to restore circulation during CPR; TR, tricuspid regurgitation;
MBTS, modified Blalock Taussig shunt; RVPAS, right ventricular to pulmonary artery shunt. *Ascending aorta size by surgeon observation. ySample sizes for TR are CPR,
31; ECMO, 48; E-CPR, 35; None, 392. zSample sizes for fractional area change are CPR, 30; ECMO, 45; E-CPR, 34; None, 394.
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cedure (P¼ .02). Open sternumwas not a risk factor for me-
diastinitis. Necrotizing enterocolitis occurred in 14 subjects
at a median of 22.5 days (range, 2-66 days) after the
Norwood procedure. No significant risk factors were
identified.ECMO and CPR
Of the 549 evaluable subjects, 22% (122/549) received
CPR (n ¼ 37), ECMO (n ¼ 49), or E-CPR (n ¼ 36) within
the first 30 days after the Norwood procedure and 78%
(427/549) did not require these interventions (‘‘none’’). Im-
portant baseline characteristics among the 4 groups are
shown in Table 3. Within the ECMO, CPR, and E-CPRFIGURE 2. Kaplan-Meier estimates for transplant-free survival after the
Norwood procedure using all available follow-up (mean, 2.7  0.9 years
for survivors). Group classification is according to extracorporeal mem-
brane oxygenation (ECMO), cardiopulmonary resuscitation (CPR),
ECMO required to restore circulation during CPR (E-CPR), and none of
these interventions (none) within the first 30 days after the Norwood pro-
cedure.
888 The Journal of Thoracic and Cardiovascular Surggroups, there was no difference in the number of subjects ac-
cording to shunt type. After the Norwood procedure, the
mean time to initiation of CPR was 3.1  1.4 days, ECMO
was 1.1  1.7 days, and E-CPR was 4.7  5.9 days. Within
theECMOsubjects, 71% (35/49) required ECMOfor failure
to separate from CPB. Low birth weight was more common
in the CPR and E-CPR groups (P<.001).
Longer-term survival for these subjects was examined
with a mean follow-up of 2.7  0.9 years. Subjects receiv-
ing CPR, ECMO, or E-CPR had a lower transplant-free sur-
vival (P < .0001; Figure 2). The 2-year transplant-free
survival was 35% for CPR, 26% for ECMO, 30% for
E-CPR, and 75% for the ‘‘none’’ group. The impact of
shunt type on transplant-free survival within the 4 groupsTABLE 4. Association of shunt type with transplant-free survival
within the 4 groups: CPR, ECMO, E-CPR and neither intervention
(none)
Hazard
ratio 95% CI P
Interaction
P*
Without adjustment
MBTS vs RVPAS
CPR 1.28 (0.89, 1.84) .94 .48
ECMO 0.82 (0.43, 1.58) .55 .15
E-CPR 0.62 (0.28, 1.36) .23 .06
None 1.42 (0.98, 2.06) .07
Adjustment for birth weight
and surgeon
MBTS vs RVPAS
CPR 1.3 (0.54, 3.16) .56 .74
ECMO 0.67 (0.33, 1.36) .26 .05
E-CPR 0.48 (0.21, 1.11) .09 .01
None 1.54 (1.04, 2.28) .03
ECMO, Extracorporeal membrane oxygenation; CPR, cardiopulmonary resuscita-
tion; E-CPR, ECMO required to restore circulation during CPR; CI, confidence inter-
val; MBTS, modified Blalock-Taussig shunt; RVPAS, right ventricle–pulmonary
artery shunt. *P value from test of interaction of shunt type and therapy group versus
none.
ery c October 2012
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ECMO had better survival with an RVPAS. After adjust-
ment for surgeon and birth weight, subjects with an
MBTS had a better outcome after E-CPR or ECMO relative
to subjects with an RVPAS compared with those subjects in
the ‘‘none’’ group. This differential effect of shunt type was
not observed for the CPR group in comparison with the
‘‘none’’ group.
DISCUSSION
The primary outcome of the SVR trial demonstrated
a transplant-free survival benefit for subjects receiving an
RVPAS, which was statistically significant at 12 months
of age but no longer significant at longer follow-up (32 
11 months).17 This prespecified secondary analysis reports
the most extensive evaluation of risk factors for morbidity
and mortality during the Norwood hospitalization in a mul-
ticenter cohort of newborn infants with HLHS and other sin-
gle right ventricular anomalies to date. Multivariable
analysis showed that only birth weight, genetic abnormality,
ECMO, and open sternum at the Norwood procedure were
independent risk factors for 30-day and hospital mortality,
and the duration of DHCA was an independent risk factor
for 30-day mortality.
Early outcomes for patients with HLHS have improved
substantially over the past 3 decades. Reports of early post-
operative mortality are predominantly from centers achiev-
ing excellent outcomes with reported surgical survivals of
81% to 93%.3,4,7-13 Results from multiple centers have
been limited to database extraction with lower survivals
of 72% to 78%.2,15,16 Reported risk factors for early
mortality after the Norwood procedure differ among
centers and include patient-related factors such as
prematurity,10 lower birth weight,2-4,7 and presence of
genetic or noncardiac abnormalities3,10; anatomic factors
such as mitral stenosis/aortic atresia,14 smaller ascending
aorta,2 restrictive atrial septum, or significant tricuspid re-
gurgitation4,7; preoperative factors such as shock7 and
ECMO10; operative factors such as older age at surgery,2
shunt type,11 longer DHCA,2 CPB, or total support
time4,14; and postoperative factors such as ECMO1,4,6,14
and low mixed venous saturation.13 An earlier surgical
era13 and lower center surgical volume2,15,16 have also
been associated with early mortality. Differences in
reported risk factors between centers may reflect variation
among centers, variation in patient populations, or studies
with small patient populations.
Of the independent risk factors that we identified for hos-
pital mortality after the Norwood procedure, lower birth
weight, genetic abnormality, longer duration of DHCA,
and ECMO have been previously reported. We did not
find the type of shunt by non–intention-to-treat analysis to
be a significant risk factor for either 30-day or Norwood
hospital mortality. These findings are consistent with theThe Journal of Thoracic and Cainitial SVR trial report in which using intention-to-treat
analysis, death, or transplant occurred within 30 days of
the Norwood procedure in 10% (28/274) of subjects with
an RVPAS compared with 14% (38/275) with an
MBTS.17 We did not find aortic atresia, size of the ascend-
ing aorta, or preoperative shock significant by univariate
analysis. Prematurity, restrictive atrial septum requiring in-
tervention, mitral stenosis/aortic atresia, moderate/severe
tricuspid regurgitation, younger age at surgery, longer total
support time, and lower center HLHS or surgeon Norwood
volumewere significant or marginally significant by univar-
iate analysis in our study; however, they were not found to
be risk factors for early mortality on multivariable analysis.
Open sternum remained significantly associated with
hospital and 30-day mortality after adjusting for other im-
portant independent risk factors including ECMO for fail-
ure to separate from CPB. Open sternum remained
a significant risk factor for mortality independent of the cen-
ter’s strategy (elective vs routine sternal closure). Few con-
flicting reports address open sternum as a risk factor for
mortality.7,21 Examination of the Society of Thoracic
Surgeons Congenital Database (n ¼ 1283, 45 centers)
found 74% of patients undergoing Norwood procedure
for HLHS were managed with an open sternum.22 Surgical
mortality did not differ between centers with a high versus
a low proportion of patients with an open sternum. In addi-
tion to mortality, we found open sternum to be an indepen-
dent risk factor for postoperative renal failure, moderate to
severe tricuspid regurgitation, longer time to first extuba-
tion, and duration of ventilation. We found the duration of
open sternum to be a risk factor for sepsis, although impor-
tantly, not for mediastinitis. The practice of elective sternal
closure is subject to selection bias; the patients chosen to
have the sternum closed at the Norwood procedure were
likely considered to be at lower risk for a poor outcome.
In addition, the practice of open sternummay serve as a sur-
rogate for variability in center clinical practices, which
were not measured in this study. The decision to close the
sternum in this trial was influenced by multiple factors, in-
cluding the center’s preference, the surgeon’s assessment,
and the use of ECMO with transthoracic cannulation.
Thus, it is not possible to infer causality between open ster-
num andmortality. However, the significantly lower mortal-
ity among patients who had their chest closed at the
conclusion of the Norwood procedure suggests that sternal
closure can be performed safely in selected patients.
Although many centers have reported risk factors for sur-
gical or hospital mortality after the Norwood procedure,
analysis of risk factors for less frequent morbidities has
been challenging owing to small sample sizes. We found
a low (<3%) incidence of necrotizing enterocolitis, hepatic
failure, and mediastinitis. Central nervous system injury, re-
nal failure, ECMO, and CPR occurred early with the me-
dian time to event less than 1 week after surgery. Hepaticrdiovascular Surgery c Volume 144, Number 4 889
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sepsis tended to occur later in the postoperative course.
The impact of center volume on mortality after the Nor-
wood procedure has been reported.15,16 However, this study
is the first multicenter report to include both center and
surgeon volumes in the risk analysis. Using the Kids’
Inpatient Database (2003, n ¼ 624 patients, 60 centers),
lower institutional HLHS volume was shown to be
a significant risk factor for Norwood hospital mortality.15
Confounding variables included in the analysis were lim-
ited. More recently, using the Society of Thoracic Surgeons
Congenital Heart Surgery Database (2011, n ¼ 2557, 53
centers), lower center Norwood procedure volume was as-
sociated with higher hospital mortality.16 We did not find
center HLHS or surgeon Norwood volume to be risk factors
for 30-day or hospital mortality. This may reflect the
different variables included in each analysis. In our analy-
sis, if the operative variable of open sternum is not divided
into elective and routine centers, then center volume
remains in the model as an independent risk factor for hos-
pital mortality. We did find volume to be a significant risk
factor for several important morbidities. Lower surgeon
Norwood volume was a risk factor for renal failure, longer
time to first extubation, and duration of ventilation; lower
center HLHS volume was a risk factor for sepsis, longer
time to first extubation, duration of ventilation, and hospital
length of stay.
Innate patient variables made up a majority of the inde-
pendent risk factors we identified for morbidity and mortal-
ity with a few risk factors potentially modifiable. Perhaps
designating a regional HLHS center could increase center/
surgeon volume. Routine preoperative intubation for trans-
port and apnea may be unnecessary and can potentially be
avoided with a lower dose of prostaglandin. Lower gesta-
tional age may be avoided by discouraging elective delivery
before 39 weeks.23
The need for CPR24 and ECMO1,4,6 is a serious
morbidity for infants with HLHS. Most commonly,
ECMO is reserved for extremely low cardiac output,
profound hypoxemia, or inability to regain spontaneous
circulation with CPR. Early survival after ECMO in
newborn infants with HLHS is reported at 17% to
54%.1,6,13,25 We found a low transplant-free survival for
subjects requiring ECMO, CPR, and E-CPR with attrition
continuing for months after Norwood procedure. Of note,
the survival of subjects requiring E-CPR did not differ
from that of subjects placed on ECMO for either failure
to separate from bypass or clinical deterioration without
CPR. Our data did not enable us to report the subset of
patients placed on ECMO for acute shunt failure, a sub-
group reported to have better survival (83%-100%).1,6
Similar to previous reports, we found improved survival
after CPR alone for the RVPAS subjects.24 In contrast,
we found that in subjects requiring ECMO or E-CPR,890 The Journal of Thoracic and Cardiovascular Surgthe MBTS was associated with a more favorable
outcome.Limitations
As study participation was limited to 15 participating
centers, performing 5 or more Norwood procedures annu-
ally, the inferences cannot be generalized to centers with
smaller case volumes. The only variable randomly assigned
was shunt type. Patients with a potentially higher risk of
mortality independent of a planned Norwood procedure
may be excluded by study criteria. Some subjects died be-
fore postoperative echocardiography, which could bias
these outcome measures. Formal genetic evaluation was
not obtained for all subjects, weakening the potential
strength of this candidate predictor. Genetic abnormality
was the only significant risk factor for central nervous sys-
tem injury, which could reflect ascertainment bias inasmuch
as these subjects were more likely to undergo cranial imag-
ing. Finally, we did not examine interactions between all
possible risk factors. There may be selected subgroups
with higher or lower risk for Norwood mortality or certain
morbidities that were not identified.CONCLUSIONS
In a large, multicenter prospective cohort of newborn in-
fants with HLHS and related right ventricular anomalies un-
dergoing the Norwood procedure as subjects of the SVR
trial, we found lower birth weight, genetic abnormality,
ECMO for failure to separate from CPB, and open sternum
to be independent risk factors for 30-day and hospital mor-
tality. Longer duration of DHCA was an independent risk
factor for 30-day mortality. Shunt type was not found to
be an independent risk factor for Norwood hospital mortal-
ity or morbidity outcomes with the exception that subjects
with an MBTS had decreased ventricular function on post-
operative echocardiography and increased odds of CPR. Pa-
tients requiring CPR and/or ECMO after the Norwood
procedure have significantly lower transplant-free survival
and remain at risk for attrition remote from the initial event.
Although most risk factors were innate patient variables,
potentially modifiable risk factors might include preopera-
tive intubation, lower gestational age, elective open ster-
num, and center/surgeon volume.References
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APPENDIX TABLE 1. Outcome variables after the Norwood procedure
Outcome N n Definition/comment
Mortality, 30 day 549 63 Includes 4 subjects who died after discharge
Hospital mortality 549 88 Mortality during or after the Norwood procedure until discharge or
stage II operation
Necrotizing enterocolitis 549 14 Defined as pneumatosis intestinalis or free air
Hepatic failure 549 16 AST, ALT, GGT>500 units
Mediastinitis 549 15 Deep sternal wound infection demonstrating sternal instability or
requiring surgical incision and drainage
Catheter intervention 549 38 Transcatheter interventions (38 subjects) included: balloon dilation
and/or stent of shunt (14), balloon dilation and/or stent of branch
pulmonary artery (5), balloon dilation of the aorta (2), balloon
dilation of the aortic valve (1), atrial radiofrequency ablation (1),
innominate artery stent (3), device placed (1) and multiple
interventions (11)
Central nervous system injury 549 47 Defined as intracranial bleed or stroke confirmed by imaging,
clinical or EEG seizure. Imaging was per clinical team
Renal failure 549 46 Creatinine>1.5 mg/dL, tripling of creatinine over<7 days or
dialysis
Sepsis 549 93 Confirmed positive blood culture
ECMO after Norwood procedure 549 56 Postoperative ECMO, excluding patients placed on ECMO during
Norwood procedure
CPR 549 97 Postoperative CPR (defined as chest compressions), excluding CPR
during Norwood procedure
Fractional area change 452 Predischarge ECHO
TR 2.5 mm 471 112 Predischarge ECHO showing TR jet 2.5 mm on one of two views
Log time to first extubation, d 447 Deaths (88) and transplants (9) were excluded. Five subjects had
insufficient data. Log transformed data was used for analyses
Log length of ventilation, d 451 Deaths (88) and transplants (9) were excluded. One subject had
insufficient data. Log transformed data was used for analyses
Log hospital length of stay, d 452 Discharge includes subjects transferred to other institutions.
Subjects who died (88) or were transplanted (9) were excluded.
Log transformed data was used for analyses.
N,Number of patients in analysis; n, number of patients with outcome; AST, aspartate aminotransferase; ALT, alanine transaminase;GGT, gamma-glutamyl transpeptidase; EEG,
electroencephalogram; ECMO, extracorporeal membrane oxygenation; CPR, cardiopulmonary resuscitation; ECHO, echocardiogram; TR, tricuspid regurgitation.
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APPENDIX TABLE 2. Candidate predictors
Candidate predictor N n Mean ± SD Definition/comment
Patient characteristics
Prenatal diagnosis 549 421
Birth weight, kg 549 3.1  0.5
Birth weight<2.5 kg 549 76
Gestational age, wk 549 38  1.6
Gestational age<37 wk 549 64
Genetic abnormality 549
Yes 29 Yes, abnormal chromosomes only (3), genetic syndrome only (21),
genetic syndrome and abnormal chromosomes (5)
No 344 No, normal chromosomes and formal genetic evaluation found no
syndrome
Unknown 176 Unknown, subjects without chromosomes or genetic evaluation
Nonsyndromic anomalies 374 268 None
38 1
25 2
43 3
Genetic abnormality and/or nonsyndromic anomalies 549
Yes 120
No 253
Unknown 176
176
Preoperative
Preoperative intubation, any 547 263 Intubation, for any reason
Preoperative intubation for apnea/transport 547 101
Preoperative intubation for shock 547 117 Intubation for shock, respiratory failure or acidosis
Preoperative left atrial decompression 549 21 Intervention on atrial septum for obstructed pulmonary venous
return
Preoperative surgical intervention 549 8 Non-cardiac surgical interventions: bowel surgery (2), chest tube
(2), other (4)
Preoperative bloodstream infection 549 8
Preoperative central nervous system injury 549 14 Defined as seizure, stroke or intracranial bleed confirmed by
imaging
Preoperative shock 547 38 See Appendix Table 2. Hepatic failure (6), renal failure (10),
elevated lactate (23), or intubation for shock (14)
Preoperative echocardiogram
Left ventricular cavity present 359 254
Fractional area change preoperatively,% 503 35  8.6 RV fractional area change
TR 2.5 mm preoperatively 506 471 Width of the tricuspid regurgitation jet 2.5 mm in either AP or
lateral view
Aortic stenosis 537 226 Flow through aortic valve
Anatomy
Aortic atresia 549 345
MS/AA 549 138 Mitral stenosis, aortic atresia. Mortality analyses only
MS/AS/IVS 549 45 Mitral stenosis, aortic stenosis with intact ventricular septum
MS/AS/VSD 549 11 Mitral stenosis, aortic stenosis with ventricular septal defect
Anomalous pulmonary venous return 549 11
Ascending aorta diameter, observed, cm 534 0.32  0.17 Surgeon observed
Ascending aorta diameter, echocardiogram, cm 534 0.36  0.18
Operative
Age at Norwood procedure, d 549 5.8  4.1
Shunt 549 Shunt in place at the end of the Norwood procedure. MBTS 268,
RVPAS 281
(Continued)
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APPENDIX TABLE 2. Continued
Candidate predictor N n Mean ± SD Definition/comment
Regional cerebral perfusion 544 Perfusion strategy unknown (5)
Yes 247 RCP alone (36), with DHCA (211)
No 297
Duration of DHCA, min 544 31.7  23.2 Subjects managed with no DHCAwere included as 0 minutes
Duration of DHCA>10 min 414 40.4  19.5 Duration of DHCA: DHCA alone (297) RCP with DHCA (117)
Duration of regional cerebral perfusion, min 546 23.7  29.2 Subjects managed with DHCA (297) alone were included as
0 minutes.
Duration of RCP, excluding DHCA alone, min 249 51.9  20.1
Total support time, min 549 143  54.1 Inclusive of CPB, DHCA, and RCP
ECMO at Norwood procedure 549 35 ECMO during Norwood procedure for failure to separate from
bypass
Perioperative
Heart block 549 13 Second- or third-degree heart block in ICU on day of Norwood
procedure
Open sternum 544 Open sternum on day of Norwood procedure
Yes, routine site 244 All sternums left open at routine site
Yes, elective site 171 Elective site with selective decision to leave sternum open
No, elective site 129 Elective site with selective decision to close sternum
Duration of open sternum, d 549 538 4.7  6.4 Thirty-four subjects died with open sternum and date of death was
used. Subjects with closed sternumwere included as 0. Eleven had
missing data
Operations after Norwood procedure 549 429 Subjects with additional surgical procedures (cardiac or other) after
the Norwood procedure and before discharge
Volume
Center volume 549 Patients with single RV screened per center per year
15 93
16 to 20 109
21 to 30 176
>30 171
Surgeon Norwood volume 549 Patients with single RV scheduled for Norwood procedure screened
per surgeon per year
5 108
6 to 10 113
11 to 15 239
>15 89
N,Number of subjects for which the data were available; n, number of subjects with a predictor or number of subjects in each category; SD, standard deviation; RV, right ventricle
(ventricular); AP, anteroposterior;MBTS,modified Blalock-Taussig shunt; RVPAS, right ventricular–pulmonary artery shunt; RCP, regional cerebral perfusion; DHCA, deep hy-
pothermic circulatory arrest; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.
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APPENDIX TABLE 3. Pediatric Heart Network Investigators
National Heart, Lung, and Blood Institute: Gail Pearson, Victoria
Pemberton, Rae-Ellen Kavey,* Mario Stylianou, Marsha Mathis.*
Network Chair: University of Texas Southwestern Medical Center, Lynn
Mahony.
Data Coordinating Center: New England Research Institutes, Lynn
Sleeper (PI), Sharon Tennstedt (PI), Steven Colan, Lisa Virzi,* Patty
Connell,* Victoria Muratov, Lisa Wruck,* Minmin Lu, Dianne
Gallagher, Anne Devine,* Julie Schonbeck, Thomas Travison,* David F.
Teitel.
Core Clinical Site Investigators: Children’s Hospital Boston, Jane W.
Newburger (PI), Peter Laussen, Pedro del Nido, Roger Breitbart, Jami
Levine, Ellen McGrath, Carolyn Dunbar-Masterson, John E. Mayer, Jr.,
Frank Pigula, Emile A. Bacha, Francis Fynn-Thompson; Children’s
Hospital of New York, Wyman Lai (PI), Beth Printz,* Daphne Hsu,*
WilliamHellenbrand, IsmeeWilliams, Ashwin Prakash,* SeemaMital,*
Ralph Mosca,* Darlene Servedio,* Rozelle Corda, Rosalind Korsin,
Mary Nash*; Children’s Hospital of Philadelphia, Victoria L. Vetter
(PI), Sarah Tabbutt,* J. William Gaynor (Study Co-Chair), Chitra
Ravishankar, Thomas Spray, Meryl Cohen, Marisa Nolan, Stephanie
Piacentino, Sandra DiLullo,* Nicole Mirarchi; Cincinnati Children’s
Medical Center, D. Woodrow Benson (PI), Catherine Dent Krawczeski,
Lois Bogenschutz, Teresa Barnard, Michelle Hamstra, Rachel Griffiths,
Kathryn Hogan, Steven Schwartz,* David Nelson, Pirooz Eghtesady*;
North Carolina Consortium: Duke University, East Carolina University,
Wake Forest University, Page A. W. Anderson (PI)—deceased, Jennifer
Li (PI), Wesley Covitz, Kari Crawford,*Michael Hines, James Jaggers,*
Theodore Koutlas, Charlie Sang, Jr., Lori Jo Sutton, Mingfen Xu;
Medical University of South Carolina, J. Philip Saul (PI), Andrew Atz,
Girish Shirali, Scott Bradley, Eric Graham, Teresa Atz, Patricia Infinger;
Primary Children’s Medical Center and the University of Utah, Salt
Lake City, Utah, L. LuAnn Minich (PI), John A. Hawkins, Michael
Puchalski, Richard V. Williams, Peter C. Kouretas, Linda M. Lambert,
Marian E. Shearrow, Jun A. Porter*;Hospital for Sick Children, Toronto,
Brian McCrindle (PI), Joel Kirsh, Chris Caldarone, Elizabeth
Radojewski, Svetlana Khaikin, Susan McIntyre, Nancy Slater;
University of Michigan, Caren S. Goldberg (PI), Richard G. Ohye (Study
Chair), Cheryl Nowak*; Children’s Hospital of Wisconsin and Medical
College of Wisconsin, Nancy S. Ghanayem (PI), James S. Tweddell,
Kathleen A. Mussatto, Michele A. Frommelt, Peter C. Frommelt, Lisa
Young-Borkowski.
Auxiliary Sites: Children’s Hospital Los Angeles, Alan Lewis (PI),
Vaughn Starnes, Nancy Pike; The Congenital Heart Institute of Florida
(CHIF), Jeffrey P. Jacobs (PI), James A. Quintessenza, Paul J. Chai,
David S. Cooper, J. Blaine John, James C. Huhta, Tina Merola, Tracey
Grifith; Emory University, WilliamMahle (PI), Kirk Kanter, Joel Bond,*
Jeryl Huckaby; Nemours Cardiac Center, Christian Pizarro (PI), Carol
Prospero; Julie Simons, Gina Baffa, Wolfgang A. Radtke; University of
Texas Southwestern Medical Center, Ilana Zeltzer (PI), Tia Tortoriello,*
Deborah McElroy, Deborah Town.
Angiography Core Laboratory: Duke University, John Rhodes, J. Curt
Fudge.
Echocardiography Core Laboratories: Children’s Hospital of
Wisconsin, Peter Frommelt; Children’s Hospital Boston, Gerald Marx.
(Continued)
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Genetics Core Laboratory: Children’s Hospital of Philadelphia,
Catherine Stolle.
Protocol Review Committee: Michael Artman (Chair); Erle Austin;
Timothy Feltes, Julie Johnson, Thomas Klitzner, Jeffrey Krischer, G.
Paul Matherne.
Data and Safety Monitoring Board: John Kugler (Chair); Rae-Ellen
Kavey,* Executive Secretary; David J. Driscoll, Mark Galantowicz,
Sally A. Hunsberger, Thomas J. Knight, Holly Taylor, Catherine L.
Webb.*
PI, Principal investigator. *No longer at the institution listed.
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